BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...
Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...
Praxis Precision Medicines, Inc. announced significant advancements in its clinical portfolio, highlighting three late-stage assets poised for potential blockbuster status and the expectation of four ...
Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating. The ...
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
On Friday, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released interim data from Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET). The Independent Data Monitoring ...
The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback